恒生创新药ETF（159316）连续9周获资金加仓，标的指数创新药“纯度”达100%

Group 1 - The adjustment of the Hang Seng Hong Kong Stock Connect Innovative Drug Index has officially taken effect, removing CXO to create a "pure" 100% innovative drug index, which more accurately reflects the overall performance of China's innovative pharmaceutical companies [1] - Historical performance of the index is expected to improve significantly after the removal of CXO, with an annualized return exceeding 47% and a higher Sharpe ratio since the index's inception [1] - Several Hong Kong innovative drug companies have reported positive mid-year results, and the outbound licensing of domestic innovative drugs has accelerated, with License out amounts reaching nearly $80 billion from January to July, a year-on-year increase of over 160% [1] Group 2 - Recent high-value licensing agreements have been reached by companies such as CSPC Pharmaceutical Group and Hansoh Pharmaceutical [1] - There has been a notable increase in capital inflow into Hong Kong innovative drug-related ETFs, with the Hang Seng Innovative Drug ETF (159316) experiencing net inflows for nine consecutive weeks, reaching a scale of over 1 billion yuan, doubling from a month ago [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only ETF product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which is expected to better assist investors in seizing industry development opportunities following the index revision [1]